News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Continue Reading Previous Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNext Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors Related Stories News LITSLINK releases guide on how to build an AI assistant News Solodev Unveils Keycloak Serverless and Managed Keycloak: Simplifying Secure Identity in the Cloud News Tom Brady Joins Cloudera as Keynote Speaker as Company Kicks Off FY26 with Game-Changing Data and AI Capabilities News Snagit and Camtasia 2025 Introduce AI and Screentelligence-Powered Workflows for Faster, More Impactful Content Creation News Kandji Announces Vulnerability Management, Delivers Stronger Security Posture for Apple in the Enterprise News Ataccama launches Ataccama Lineage to deliver end-to-end visibility into data flows